Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Despite its rarity, it is important for doctors to be aware of the signs and symptoms of AFX, as early diagnosis and treatment are critical for successful outcomes.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer. It is a type of soft-tissue sarcoma, which is a cancer that develops in the connective tissues of the body. AFX is most commonly found in elderly individuals and can be found in any area of the body, although it is most commonly found on the head or neck. It is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration.
The most common sign of AFX is a rapidly growing, red-brown to yellow-brown papule or nodule. This lesion may be tender to the touch and may have a central ulceration. Other signs and symptoms of AFX may include itching, bleeding, and pain. The lesion may also be accompanied by a reddish-brown halo or a crusty, flaky surface.
Diagnosis of AFX begins with a physical examination. During the physical exam, the doctor will examine the lesion and may take a biopsy. A biopsy is a procedure in which a small sample of the lesion is removed and sent to a laboratory for further examination. The laboratory will examine the sample under a microscope and may order additional tests to confirm the diagnosis.
The primary treatment for AFX is surgical excision. This involves surgically removing the lesion and any surrounding tissue. In some cases, radiation therapy may be used to reduce the size of the lesion prior to surgery. In cases where the lesion is too large to be removed surgically, chemotherapy may be used to shrink the tumor.
Unfortunately, there is no known way to prevent AFX. However, it is important to practice sun safety and to avoid prolonged exposure to ultraviolet (UV) radiation. This includes wearing sunscreen and protective clothing when outdoors, avoiding tanning beds, and avoiding direct sun exposure during peak UV hours. Additionally, it is important to monitor any changes in the skin and to seek medical attention if any suspicious lesions are found.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Early diagnosis and treatment are critical for successful outcomes, so it is important for doctors to be aware of the signs and symptoms of AFX. While there is no known way to prevent AFX, it is important to practice sun safety and to monitor any changes in the skin.
1.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
2.
Some triple negative breast cancers might be avoided by longer breastfeeding
3.
Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy
4.
FDA Greenlights First Engineered Cell Therapy for a Solid Tumor
5.
Headlines About Doc Who 'Catches' Patient's Cancer Are Popping Up Again
1.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
2.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
3.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
4.
Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools
5.
Mastering Surgical Oncology: Education, Certification, Trials, and Therapy Insights
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation